World's largest public-private antibiotic fund unveils first investments

The AMR Action Fund, established in the summer of 2020 by an extensive consortium of some of the world’s leading pharmaceutical companies including Novo Nordisk, is ready to announce its first two investments in the first against antimicrobial resistance (AMR).
Photo: Daniel Karmann/AP/Ritzau Scanpix
Photo: Daniel Karmann/AP/Ritzau Scanpix
by albert rønning-andersson, translated by daniel pedersen

Around two years after the AMR Action Fund came into existence with the goal of aiding the development of new antibiotic drugs, the fund has announced its first two investments, a press release reports.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading